MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
AZTA stock logo

AZTA

Azenta, Inc.

$22.63
1.45
 (6.85%)
Exchange:  NASDAQ
Market Cap:  1.042B
Shares Outstanding:  4.688M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Instruments & Supplies
   
CEO:  John Marotta
Full Time Employees:  3000
Address: 
15 Elizabeth Drive
Burlington
MA
1824
US
Website:  https://www.azenta.com
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment’s services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/02/05 — 1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue665,072573,448593,821
Gross Profit233,256254,622270,280
EBITDA55,15171,61954,066
Operating Income-82,198-29,981-11,268
Net Income-14,257-164,897-55,763

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets2,885,7202,100,0412,059,582
Total Liabilities351,220331,074332,596
Total Stockholders Equity2,534,5001,768,9671,726,986
Total Debt60,43670,67651,244
Cash and Cash Equivalents678,910310,929279,783

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow17,49050,28972,181
Capital Expenditure-39,436-37,392-33,857
Free Cash Flow-21,94612,89738,324
Net Income-14,257-164,170-59,503
Net Change in Cash-357,251-363,055-24,305

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)733,315.873Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)748,570.197Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)742,800Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)128,440.290Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)131,112.085Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)130,101.435Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)79,436.339Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)81,592.533Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)80,776.961Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)302,611.623Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)308,906.503Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)306,525.362Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.760Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)1.780Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)1.730Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)2Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
656.323M  ?P/S
 (TTM)
: 
1.94
?Net Income
 (TTM)
: 
-164170000  ?P/E
 (TTM)
: 
-19.89
?Enterprise Value
 (TTM)
: 
923.28M  ?EV/FCF
 (TTM)
: 
29.85
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.03  ?ROIC
 (TTM)
: 
0.04
?Net Debt
 (TTM)
: 
-411184000  ?Debt/Equity
 (TTM)
: 
0.06
?P/B
 (TTM)
: 
0.67  ?Current Ratio
 (TTM)
: 
2.92

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
29.01Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates AZTA intrinsic value between $3.57 – $3.61 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate AZTA Intrinsic Value

Common questions about AZTA valuation

Is Azenta, Inc. (AZTA) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Azenta, Inc. (AZTA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is AZTA a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AZTA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is AZTA’s P/E ratio?

You can see AZTA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for AZTA?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is AZTA a good long-term investment?

Whether AZTA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

AZTA

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

6.85
MARKETSnap

Trading Metrics:

Open: 20.81   Previous Close: 21.18
Day Low: 20.4   Day High: 22.66
Year Low: 19.87   Year High: 41.73
Price Avg 50: 27.44   Price Avg 200: 31.06
Volume: 1.111M   Average Volume: 961634

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Assenagon Asset Management S.A. Increases Stock Holdings in Azenta, Inc. $AZTA
30-03-2026 03:17
Assenagon Asset Management S.A. Increases Stock Holdings in Azenta, Inc. $AZTA
Azenta, Inc. (AZTA) M&A Call Transcript
10-03-2026 13:50
Azenta, Inc. (AZTA) M&A Call Transcript
Brokerages Set Azenta, Inc. (NASDAQ:AZTA) Price Target at $41.33
05-03-2026 02:52
Brokerages Set Azenta, Inc. (NASDAQ:AZTA) Price Target at $41.33
Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities
04-03-2026 09:11
Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities
Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure
09-02-2026 16:05
Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure
Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast
21-01-2026 16:05
Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read